Brilliant Acquisition Price, Forecast, Insider, Ratings, Fundamentals & Signals

New york--(business wire)---- $brli #fintech--nukkleus inc. (nasdaq: nukk), a pioneering force in the fintech industry, is excited to announce that it has signed a term sheet for the acquisition of mercury global, a leading cross-border payments firm with operations in london and south africa. this significant step marks nukkleus' strategic move to further strengthen its presence in the dynamic world of cross-border payments. under the proposed agreement, nukkleus is set to acquire the entire issued share capital.

New york , nov. 30, 2023 /prnewswire/ -- nukkleus, inc. (formerly compliance & risk management solutions inc.) (otc: nukk) proudly announces the completion of its strategic merger with brilliant acquisition corp (nasdaq: brli), marking a significant milestone in the financial technology landscape. this merger, valuing nukkleus at around $105 million, signifies a bold step into a future rich with digital asset opportunities for businesses and investors alike.

New york, nov. 22, 2023 (globe newswire) -- brilliant acquisition corporation (“brilliant”) announced today that it has extended the period of time it will have to consummate its initial business combination by a further one month, or until december 23, 2023. in connection with the extension, brilliant's sponsor, nisun investment holding limited, and nukkleus inc. (“nukkleus”) deposited an aggregate of $32,300 in brilliant's trust account, representing $0.08 per public ordinary share of brilliant currently outstanding, as additional interest on the proceeds in the trust account. the extension was approved by brilliant's shareholders on july 20, 2023.

New york, sept. 22, 2023 (globe newswire) --  brilliant acquisition corporation (“brilliant”) announced today that it has extended the period of time it will have to consummate its initial business combination by a further one month, or until october 23, 2023. in connection with the extension, nukkleus inc. (“nukkleus”) deposited $32,300 in brilliant's trust account, representing $0.08 per public ordinary share of brilliant currently outstanding, as additional interest on the proceeds in the trust account. the extension was approved by brilliant's shareholders on july 20, 2023. the shareholder approval also permits brilliant to further extend brilliant's initial business combination deadline on a monthly basis up to a further two months, or until december 23, 2023, upon deposit of an additional $32,300 in the trust account for each month.

New york, aug. 23, 2023 (globe newswire) -- brilliant acquisition corporation (“brilliant”) announced today that it has extended the period of time it will have to consummate its initial business combination by a further one month, or until september 23, 2023. in connection with the extension, brilliant's sponsor, nisun investment holding limited, and nukkleus inc. (“nukkleus”) deposited an aggregate of $32,300 in brilliant's trust account, representing $0.08 per public ordinary share of brilliant currently outstanding, as additional interest on the proceeds in the trust account. the extension was approved by brilliant's shareholders on july 20, 2023. the shareholder approval also permits brilliant to further extend brilliant's initial business combination deadline on a monthly basis up to a further three months, or until december 23, 2023, upon deposit of an additional $32,300 in the trust account for each month.

Nukkleus, which works on acquiring and scaling high-potential blockchain, digital and multi-asset businesses for retail and institutional markets, has debuted its new website and brand, which will put the firm's subsidiary brands under the same suite of assets, a press release said. This comes as the company has proposed to combine with Brilliant Acquisition Corp., […]

New York, July 20, 2020 -- Brilliant Acquisition Corporation (Nasdaq: BRLIU, the “Company”) announced today that, commencing on July 22, 2020, the holders of the 4,600,000.

Brilliant Acquisition Corporation (Nasdaq: BRLIU, the “Company”) announced today that it closed the full 600,000 unit over-allotment option of its initial public offering of 4,000,000 units, which itself closed on June 26, 2020. The Company’s units began trading on the Nasdaq Capital Market (“Nasdaq”) on June 24, 2020 and trade under the ticker symbol “BRLIU.” Each unit consists of one ordinary share, one right entitling the holder to 1/10 of one ordinary share, and one warrant to purchase one ordinary share at a price of $11.50.

Brilliant Acquisition Corporation (Nasdaq: BRLIU, the “Company”) announced today that it closed its initial public offering of 4,000,000 units. The Company’s units began trading on the Nasdaq Capital Market (“Nasdaq”) on June 24, 2020 and trade under the ticker symbol “BRLIU.” Each unit consists of one ordinary share, one right entitling the holder to 1/10 of one ordinary share, and one warrant to purchase one ordinary share at a price of $11.50.

Brilliant Acquisition Corporation (NASADAQ: BRLIU) (the “Company”) announced today that its Registration Statement on Form S-1 (SEC File No. 333-237153), as amended, was declared effective by the Securities and Exchange Commission. The closing of the Company’s initial public offering of 4,000,000 units is expected to occur on or about June 26, 2020. Each unit consists of one ordinary share, no par value per share (“Ordinary Share”), one right, with each right entitling the holder to 1/10 of one Ordinary Share, and one warrant, with each warrant entitling the holder to purchase one Ordinary Share at a price of $11.50 per share.

MIAMI, April 30, 2020 -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2020, as well as discuss financial.

The lawsuit claims that the company’s security posture led to investor losses.

Opko Health (NASDAQ:OPK)‘s stock had its “buy” rating reissued by equities research analysts at Piper Sandler in a research report issued to clients and investors on Wednesday, TipRanks reports. They presently have a $3.00 target price on the biotechnology company’s stock. Piper Sandler’s price target indicates a potential upside of 33.33% from the stock’s current […]

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced that beginning today it will offer antibody blood tests to detect an immune response after infection with the COVID-19 virus. Antibody testing and molecular diagnostic testing for COVID-19 are available to healthcare providers

Opko's BioReference Laboratories initiates testing for COVID-19 antibodies OPK